Edwards Launches Magna Mitral Heart Valve Following FDA Approval
This article was originally published in The Gray Sheet
Executive Summary
Edwards LifeSciences will launch its Perimount Magna Mitral heart valve immediately now that it has received PMA supplement approval, the firm announced Sept. 3
You may also be interested in...
Edwards’ Sapien Sales Drive 24% Gain In Q2 Heart Valve Revenue
Edwards Lifesciences' heart valve sales soared 24% in the second quarter from a year ago, to $162.6 million, driven by European sales of its Sapien transcatheter heart valve, the company says
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.